Early Progressing Follicular Lymphoma

Wallace, Danielle; Casulo, Carla

doi:10.1007/s11912-021-01126-7

Cited by 5 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, R‐CHOP was more commonly used as 2nd line treatment for patients with POD24 compared with patients with later relapse, indicating a clinically more high‐risk disease. Predictive markers for risk of early progression/relapse and for identifying patients who will have long‐lasting remission to specific 1st line treatments in FL remain to be determined [ 6 , 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study

Wästerlid,

Dietrich,

Oksanen

et al. 2024

eJHaem

View full text Add to dashboard Cite

Follicular lymphoma (FL) is a clinically heterogeneous disease. The need for treatment, treatment sequencing, number of treatment lines, and its association with survival have not been described in a population‐based setting. We identified all patients diagnosed with FL in the Swedish Lymphoma register from 2007 to 2014, followed until 2020, with detailed data on progression/relapse, transformation, and 2nd and further lines of therapy. During a median follow‐up of 6.8 years, 1226 patients (69%) received 1st systemic treatment, 358 patients (20%) were managed with watch‐and‐wait (WaW) only, and 188 (10%) patients were treated with radiotherapy and did not require additional therapy during the study period. Among patients starting systemic treatment, 496 (40%), 224 (18%), and 88 (7%) received 2nd‐, 3rd‐, or 4th‐line therapy, respectively. The 10‐year cause‐specific cumulative incidence of transformation was 13%. Among patients managed with 1st line R‐single, R‐CHOP, or BR, 54%, 33%, and 29% required 2nd line, respectively. The cumulative probability of starting subsequent treatment within 2 years was 26% after 1st line and 35% after 2nd line treatment. Two‐year OS following 1st, 2nd, 3rd, and 4th line systemic treatment was 84%, 70%, 52%, and 36%, respectively, and remained similar when excluding transformations. We conclude that a substantial proportion of FL patients can be managed with WaW for a long period of time, while patients who require multiple treatment lines constitute a group with a large clinical unmet need. These results constitute valuable real‐world reference data for FL.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study

Wästerlid,

Dietrich,

Oksanen

et al. 2024

eJHaem

View full text Add to dashboard Cite

show abstract

“…Integrated models that combine clinical and molecular factors have also been proposed, including m7-FLIPI, POD24-PI and a 23-gene model 34 , 129 , 130 . The sensitivity and specificity of these models in predicting POD24 range from 43% to 86%, with the highest sensitivity for POD24-PI (78%) and specificity for m7-FLIPI (86%) 129 , 131 . t-FL is also found relative to a range of clinical factors, including high histological grade and high FLIPI score, while the response to therapy had no impact on the risk of transformation 112 .…”

Section: Pod24 and Transformed Fl: Underlying Mechanism And Biomarkersmentioning

confidence: 99%

Advances in the multi-omics landscape of follicular lymphoma

Xu¹,

Zheng²,

Zhao³

2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Follicular lymphoma (FL) is the most common indolent lymphoma originating from germinal center B cells. FL represents a clinically and biologically heterogeneous disease. Most patients have favorable outcomes, but a subset of patients experiences early progression or transformation and has a poor prognosis. Abnormalities in FL cells and tumor microenvironment have been revealed using multi-omics techniques, including genomic, epigenomic, transcriptomic and proteomic analysis. Recurrent somatic gene aberrations mainly involve epigenetic modifiers, transcription factors, oncogenic pathways and microenvironment modulators. Single-cell transcriptomic analysis show marked inter- and intra-patient FL subclone heterogeneity. In addition, a comprehensive profile of microenvironmental components is provided, unveiling the crosstalk between tumor and microenvironment that induce FL progression and facilitate immune escape. Together, these studies provide insights into the mechanisms and biomarkers of high-risk FL populations, as well as the potential targeted and immunotherapy options. Future research should focus on integrating multi-omics aberrations to optimize therapeutic strategies in FL.

show abstract

Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma

Shen

Pan

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

Early Progressing Follicular Lymphoma

Cited by 5 publications

References 54 publications

Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study

Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study

Advances in the multi-omics landscape of follicular lymphoma

Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma

Contact Info

Product

Resources

About